Prevents pregnancy. ANDA 209031, held by Glenmark Speclt. Ethinyl Estradiol; Norethindrone Acetate.
As of Nov 16, 2026, ANDA 209031 (Hailey Fe 1.5/30), held by Glenmark Speclt, was first approved by FDA on Jun 5, 2018, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Hailey Fe 1.5/30 is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Oral contraceptives are highly effective. Table 1 lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 5, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Hailey Fe 1.5/300.03MG;1.5MG · tablet;oral-28 | Ethinyl Estradiol; Norethindrone Acetate | Rx |
| Jul 14, 2023 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jul 14, 2023 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jun 5, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters